Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin
We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30 Klebsiella pneumoniae , 30 Pseudomonas aeruginosa, and 30 Acinetobacter baumannii multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard labora...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2008-06, Vol.27 (6), p.439-443 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 443 |
|---|---|
| container_issue | 6 |
| container_start_page | 439 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 27 |
| creator | Falagas, M. E. Kanellopoulou, M. D. Karageorgopoulos, D. E. Dimopoulos, G. Rafailidis, P. I. Skarmoutsou, N. D. Papafrangas, E. A. |
| description | We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30
Klebsiella pneumoniae
, 30
Pseudomonas aeruginosa,
and 30
Acinetobacter baumannii
multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard laboratory methods were used for susceptibility testing to commonly used antibiotics and the detection of extended-spectrum-
β
-lactamase (ESBL) and metallo-
β
-lactamase (MBL) production. The minimum inhibitory concentration (MIC) of fosfomycin for each isolate was determined by the agar dilution method. All
K. pneumoniae
isolates were both ESBL and MBL producers; all
P. aeruginosa
isolates were ESBL producers. The
K. pneumoniae
strains had fosfomycin MICs distributed across a range of 8-64 μg/ml; MIC
50
was 16 μg/ml and MIC
90
32 μg/ml. The fosfomycin MICs of the
P. aeruginosa
strains had a distribution across a range of 4 to over 512 μg/ml; MIC
50
was 32 μg/ml and MIC
90
128 μg/ml. The fosfomycin MICs of the
A. baumannii
strains had a distribution across a range of 64 to over 512 μg/ml; MIC
50
was 256 μg/ml and MIC
90
more than 512 μg/ml. Although standardized fosfomycin MIC interpretative breakpoints for the species studied are lacking, the findings of our study support the idea that fosfomycin may be further investigated as one among a decreasing list of therapeutic options for the treatment of infections due to multidrug-resistant strains of, primarily,
K. pneumoniae
and, secondly,
P. aeruginosa
. |
| doi_str_mv | 10.1007/s10096-007-0456-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954594051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897844811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-f3d77877d8a934c1d76bfbbf4fe5bd31d5f41f322e917b7938e2589c4f6eb7eb3</originalsourceid><addsrcrecordid>eNp9kV1LBCEUhiWK2j5-QDcxBNWVpaOO42VEXxB0U9CdqKOLy3xs6gT773PYpYWgbvSAzznnfX0BOMXoGiPEb2I-RQVzCRFlFaQ7YIYpYZASTnbBDAlCoeAlOQCHMS5QBmvO98EBrktMGatn4OO2T77zJgzaq7aIYzR2mbz2rU-rYnBFN7bJN2Gcw2Cjj0n1qXgMqit6O1fJf9lCK5Ns8KpIQ-GG6IZuZXx_DPacaqM92dxH4P3h_u3uCb68Pj7f3b5AQwVP0JGGT6KaWmWxBje80k5rR51luiG4YY5iR8rSCsw1F6S2JauFoa6ymltNjsDVeu4yDJ-jjUl2PntoW9XbYYxSMMoERQxn8vJfkiNOMUcog-e_wMUwhj67kCWuKyGqcoLwGspfF2OwTi6D71RYSYzklI5cpyOnckpH0txzthk86s42245NHBm42AAqGtW6oHrj4w-X11ZM8MlKueZifurnNmwV_r39G3_QqDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218699620</pqid></control><display><type>article</type><title>Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Falagas, M. E. ; Kanellopoulou, M. D. ; Karageorgopoulos, D. E. ; Dimopoulos, G. ; Rafailidis, P. I. ; Skarmoutsou, N. D. ; Papafrangas, E. A.</creator><creatorcontrib>Falagas, M. E. ; Kanellopoulou, M. D. ; Karageorgopoulos, D. E. ; Dimopoulos, G. ; Rafailidis, P. I. ; Skarmoutsou, N. D. ; Papafrangas, E. A.</creatorcontrib><description>We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30
Klebsiella pneumoniae
, 30
Pseudomonas aeruginosa,
and 30
Acinetobacter baumannii
multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard laboratory methods were used for susceptibility testing to commonly used antibiotics and the detection of extended-spectrum-
β
-lactamase (ESBL) and metallo-
β
-lactamase (MBL) production. The minimum inhibitory concentration (MIC) of fosfomycin for each isolate was determined by the agar dilution method. All
K. pneumoniae
isolates were both ESBL and MBL producers; all
P. aeruginosa
isolates were ESBL producers. The
K. pneumoniae
strains had fosfomycin MICs distributed across a range of 8-64 μg/ml; MIC
50
was 16 μg/ml and MIC
90
32 μg/ml. The fosfomycin MICs of the
P. aeruginosa
strains had a distribution across a range of 4 to over 512 μg/ml; MIC
50
was 32 μg/ml and MIC
90
128 μg/ml. The fosfomycin MICs of the
A. baumannii
strains had a distribution across a range of 64 to over 512 μg/ml; MIC
50
was 256 μg/ml and MIC
90
more than 512 μg/ml. Although standardized fosfomycin MIC interpretative breakpoints for the species studied are lacking, the findings of our study support the idea that fosfomycin may be further investigated as one among a decreasing list of therapeutic options for the treatment of infections due to multidrug-resistant strains of, primarily,
K. pneumoniae
and, secondly,
P. aeruginosa
.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-007-0456-4</identifier><identifier>PMID: 18214558</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Acinetobacter baumannii ; Agar ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobial activity ; Antimicrobial agents ; Bacteria ; beta-Lactam Resistance - genetics ; beta-Lactamases - genetics ; beta-Lactamases - metabolism ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breakpoints ; Clinical isolates ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; fosfomycin ; Fosfomycin - pharmacology ; Gram-negative bacteria ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacteria - isolation & purification ; Hospitals ; Infection ; Infectious diseases ; Internal Medicine ; Klebsiella pneumoniae ; Laboratories ; Laboratory methods ; Medical Microbiology ; Medical sciences ; Metal concentrations ; Metallo- beta -lactamase ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Pathogens ; Pharmacology. Drug treatments ; Pseudomonas aeruginosa</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2008-06, Vol.27 (6), p.439-443</ispartof><rights>Springer-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-f3d77877d8a934c1d76bfbbf4fe5bd31d5f41f322e917b7938e2589c4f6eb7eb3</citedby><cites>FETCH-LOGICAL-c497t-f3d77877d8a934c1d76bfbbf4fe5bd31d5f41f322e917b7938e2589c4f6eb7eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-007-0456-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-007-0456-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20365971$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18214558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falagas, M. E.</creatorcontrib><creatorcontrib>Kanellopoulou, M. D.</creatorcontrib><creatorcontrib>Karageorgopoulos, D. E.</creatorcontrib><creatorcontrib>Dimopoulos, G.</creatorcontrib><creatorcontrib>Rafailidis, P. I.</creatorcontrib><creatorcontrib>Skarmoutsou, N. D.</creatorcontrib><creatorcontrib>Papafrangas, E. A.</creatorcontrib><title>Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30
Klebsiella pneumoniae
, 30
Pseudomonas aeruginosa,
and 30
Acinetobacter baumannii
multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard laboratory methods were used for susceptibility testing to commonly used antibiotics and the detection of extended-spectrum-
β
-lactamase (ESBL) and metallo-
β
-lactamase (MBL) production. The minimum inhibitory concentration (MIC) of fosfomycin for each isolate was determined by the agar dilution method. All
K. pneumoniae
isolates were both ESBL and MBL producers; all
P. aeruginosa
isolates were ESBL producers. The
K. pneumoniae
strains had fosfomycin MICs distributed across a range of 8-64 μg/ml; MIC
50
was 16 μg/ml and MIC
90
32 μg/ml. The fosfomycin MICs of the
P. aeruginosa
strains had a distribution across a range of 4 to over 512 μg/ml; MIC
50
was 32 μg/ml and MIC
90
128 μg/ml. The fosfomycin MICs of the
A. baumannii
strains had a distribution across a range of 64 to over 512 μg/ml; MIC
50
was 256 μg/ml and MIC
90
more than 512 μg/ml. Although standardized fosfomycin MIC interpretative breakpoints for the species studied are lacking, the findings of our study support the idea that fosfomycin may be further investigated as one among a decreasing list of therapeutic options for the treatment of infections due to multidrug-resistant strains of, primarily,
K. pneumoniae
and, secondly,
P. aeruginosa
.</description><subject>Acinetobacter baumannii</subject><subject>Agar</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobial activity</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>beta-Lactam Resistance - genetics</subject><subject>beta-Lactamases - genetics</subject><subject>beta-Lactamases - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breakpoints</subject><subject>Clinical isolates</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>fosfomycin</subject><subject>Fosfomycin - pharmacology</subject><subject>Gram-negative bacteria</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacteria - isolation & purification</subject><subject>Hospitals</subject><subject>Infection</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Klebsiella pneumoniae</subject><subject>Laboratories</subject><subject>Laboratory methods</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Metal concentrations</subject><subject>Metallo- beta -lactamase</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Pathogens</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas aeruginosa</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kV1LBCEUhiWK2j5-QDcxBNWVpaOO42VEXxB0U9CdqKOLy3xs6gT773PYpYWgbvSAzznnfX0BOMXoGiPEb2I-RQVzCRFlFaQ7YIYpYZASTnbBDAlCoeAlOQCHMS5QBmvO98EBrktMGatn4OO2T77zJgzaq7aIYzR2mbz2rU-rYnBFN7bJN2Gcw2Cjj0n1qXgMqit6O1fJf9lCK5Ns8KpIQ-GG6IZuZXx_DPacaqM92dxH4P3h_u3uCb68Pj7f3b5AQwVP0JGGT6KaWmWxBje80k5rR51luiG4YY5iR8rSCsw1F6S2JauFoa6ymltNjsDVeu4yDJ-jjUl2PntoW9XbYYxSMMoERQxn8vJfkiNOMUcog-e_wMUwhj67kCWuKyGqcoLwGspfF2OwTi6D71RYSYzklI5cpyOnckpH0txzthk86s42245NHBm42AAqGtW6oHrj4w-X11ZM8MlKueZifurnNmwV_r39G3_QqDQ</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Falagas, M. E.</creator><creator>Kanellopoulou, M. D.</creator><creator>Karageorgopoulos, D. E.</creator><creator>Dimopoulos, G.</creator><creator>Rafailidis, P. I.</creator><creator>Skarmoutsou, N. D.</creator><creator>Papafrangas, E. A.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7T7</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20080601</creationdate><title>Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin</title><author>Falagas, M. E. ; Kanellopoulou, M. D. ; Karageorgopoulos, D. E. ; Dimopoulos, G. ; Rafailidis, P. I. ; Skarmoutsou, N. D. ; Papafrangas, E. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-f3d77877d8a934c1d76bfbbf4fe5bd31d5f41f322e917b7938e2589c4f6eb7eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acinetobacter baumannii</topic><topic>Agar</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobial activity</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>beta-Lactam Resistance - genetics</topic><topic>beta-Lactamases - genetics</topic><topic>beta-Lactamases - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breakpoints</topic><topic>Clinical isolates</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>fosfomycin</topic><topic>Fosfomycin - pharmacology</topic><topic>Gram-negative bacteria</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacteria - isolation & purification</topic><topic>Hospitals</topic><topic>Infection</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Klebsiella pneumoniae</topic><topic>Laboratories</topic><topic>Laboratory methods</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Metal concentrations</topic><topic>Metallo- beta -lactamase</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Pathogens</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas aeruginosa</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Falagas, M. E.</creatorcontrib><creatorcontrib>Kanellopoulou, M. D.</creatorcontrib><creatorcontrib>Karageorgopoulos, D. E.</creatorcontrib><creatorcontrib>Dimopoulos, G.</creatorcontrib><creatorcontrib>Rafailidis, P. I.</creatorcontrib><creatorcontrib>Skarmoutsou, N. D.</creatorcontrib><creatorcontrib>Papafrangas, E. A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falagas, M. E.</au><au>Kanellopoulou, M. D.</au><au>Karageorgopoulos, D. E.</au><au>Dimopoulos, G.</au><au>Rafailidis, P. I.</au><au>Skarmoutsou, N. D.</au><au>Papafrangas, E. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>27</volume><issue>6</issue><spage>439</spage><epage>443</epage><pages>439-443</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30
Klebsiella pneumoniae
, 30
Pseudomonas aeruginosa,
and 30
Acinetobacter baumannii
multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard laboratory methods were used for susceptibility testing to commonly used antibiotics and the detection of extended-spectrum-
β
-lactamase (ESBL) and metallo-
β
-lactamase (MBL) production. The minimum inhibitory concentration (MIC) of fosfomycin for each isolate was determined by the agar dilution method. All
K. pneumoniae
isolates were both ESBL and MBL producers; all
P. aeruginosa
isolates were ESBL producers. The
K. pneumoniae
strains had fosfomycin MICs distributed across a range of 8-64 μg/ml; MIC
50
was 16 μg/ml and MIC
90
32 μg/ml. The fosfomycin MICs of the
P. aeruginosa
strains had a distribution across a range of 4 to over 512 μg/ml; MIC
50
was 32 μg/ml and MIC
90
128 μg/ml. The fosfomycin MICs of the
A. baumannii
strains had a distribution across a range of 64 to over 512 μg/ml; MIC
50
was 256 μg/ml and MIC
90
more than 512 μg/ml. Although standardized fosfomycin MIC interpretative breakpoints for the species studied are lacking, the findings of our study support the idea that fosfomycin may be further investigated as one among a decreasing list of therapeutic options for the treatment of infections due to multidrug-resistant strains of, primarily,
K. pneumoniae
and, secondly,
P. aeruginosa
.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18214558</pmid><doi>10.1007/s10096-007-0456-4</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2008-06, Vol.27 (6), p.439-443 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954594051 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acinetobacter baumannii Agar Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobial activity Antimicrobial agents Bacteria beta-Lactam Resistance - genetics beta-Lactamases - genetics beta-Lactamases - metabolism Biological and medical sciences Biomedical and Life Sciences Biomedicine Breakpoints Clinical isolates Drug resistance Drug Resistance, Multiple, Bacterial fosfomycin Fosfomycin - pharmacology Gram-negative bacteria Gram-Negative Bacteria - drug effects Gram-Negative Bacteria - isolation & purification Hospitals Infection Infectious diseases Internal Medicine Klebsiella pneumoniae Laboratories Laboratory methods Medical Microbiology Medical sciences Metal concentrations Metallo- beta -lactamase Microbial Sensitivity Tests Minimum inhibitory concentration Pathogens Pharmacology. Drug treatments Pseudomonas aeruginosa |
| title | Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A38%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20susceptibility%20of%20multidrug-resistant%20Gram%20negative%20bacteria%20to%20fosfomycin&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Falagas,%20M.%20E.&rft.date=2008-06-01&rft.volume=27&rft.issue=6&rft.spage=439&rft.epage=443&rft.pages=439-443&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-007-0456-4&rft_dat=%3Cproquest_cross%3E1897844811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218699620&rft_id=info:pmid/18214558&rfr_iscdi=true |